# A Bioequivalence Study to Compare Two Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects

> **NCT04527484** · PHASE1 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 130 (estimated)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** SHR-1314

## Key facts

- **NCT ID:** NCT04527484
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-20
- **Primary completion:** 2021-01-10
- **Final completion:** 2021-03-30
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2020-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04527484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04527484, "A Bioequivalence Study to Compare Two Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04527484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*